Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapansutrile in Schnitzler's Syndrome
NCT03595371Phase 2Terminated
- Sponsor
- Olatec Therapeutics LLC
- Start
- May 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dapansutrile in Schnitzler syndrome, sponsored by Olatec Therapeutics LLC. Primary endpoint: Schnitzler's Syndrome Symptom Index at Day 14. Started May 2018; status: terminated.
02
Drugs
dapansutrile
03
Conditions
Schnitzler syndrome
Beyond the preview
Go deeper on NCT03595371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03595371.